Montanaro Asset Management Ltd Reduces Stake in Masimo Co. (NASDAQ:MASI)

Montanaro Asset Management Ltd cut its holdings in shares of Masimo Co. (NASDAQ:MASI) by 16.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 46,500 shares of the medical equipment provider’s stock after selling 9,200 shares during the period. Masimo accounts for 1.6% of Montanaro Asset Management Ltd’s portfolio, making the stock its 28th biggest position. Montanaro Asset Management Ltd owned approximately 0.09% of Masimo worth $7,686,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jones Financial Companies Lllp purchased a new position in Masimo during the 4th quarter valued at $27,000. UMB Bank n.a. boosted its stake in shares of Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont purchased a new position in shares of Masimo during the fourth quarter valued at about $33,000. Blue Trust Inc. raised its stake in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 64 shares during the period. Institutional investors own 85.96% of the company’s stock.

Insider Activity at Masimo

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by insiders.

Masimo Price Performance

Shares of NASDAQ:MASI opened at $166.42 on Thursday. The company has a market capitalization of $8.98 billion, a PE ratio of 114.77 and a beta of 1.04. The business has a fifty day moving average price of $174.99 and a 200-day moving average price of $160.65. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $194.88. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. As a group, equities analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

Analyst Ratings Changes

MASI has been the topic of a number of research analyst reports. Wells Fargo & Company upped their target price on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Raymond James upped their price target on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Finally, Piper Sandler upped their target price on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Masimo currently has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.